期刊
NEW BIOTECHNOLOGY
卷 52, 期 -, 页码 42-53出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nbt.2019.04.002
关键词
Immunocytokines; Antibody-fusion proeins; Targeted delivery; Cytokines; Cancer; Chronic inflammation; Immunotherapy; Immunemodulation
资金
- European Research Council Advanced Grant Zauberkugel [670603]
- Swiss National Science Foundation [310030B_163479/1, SINERGIA CRSII2_160699/1]
- ETH Zurich
- European Research Council (ERC) [670603] Funding Source: European Research Council (ERC)
Antibody-cytokine fusion proteins represent a novel class of biopharmaceuticals, with the potential to increase the therapeutic index of cytokine 'payloads' and to promote leukocyte infiltration at the site of disease. In this review, we present a survey of immunocytokines that have been used in preclinical models of cancer and in clinical trials. In particular, we highlight how antibody format, choice of target antigen and cytokine engineering, as well as combination strategies, may have a profound impact on therapeutic performance. Moreover, by using anti-inflammatory cytokines, antibody fusion strategies can conveniently be employed for the treatment of auto-immune and chronic inflammatory conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据